FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Larry Norton

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
X Qian; Jeffrey E Segall; T Smirnova; Kimita Suyama; Z N Zhou; James Hulit; Joseph Locker; Olivier D Loudig; Larry Norton; Greg R Phillips; Thomas J Belbin; Eliseo Eugenin; Rachel B Hazan
p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis.
Catherine E Mosher; Larry Norton; Maura Dickler; Courtney Johnson; Mary Jane Massie; Katherine N DuHamel
Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae.
Paul K Newton; Jorge Nieva; Larry Norton; Lyudmila Bazhenova; Kelly Bethel; Jeremy Mason; Peter Kuhn
Spreaders and sponges define metastasis in lung cancer: a markov chain monte carlo mathematical model.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Larry Norton (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: X Qian; Jeffrey E Segall; T Smirnova; Kimita Suyama; Z N Zhou; James Hulit; Joseph Locker; Olivier D Loudig; Larry Norton; Greg R Phillips; Thomas J Belbin; Eliseo Eugenin; Rachel B Hazan
p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis.
Oncogene 2013;32(18):2292-303.
2013: Catherine E Mosher; Larry Norton; Maura Dickler; Courtney Johnson; Mary Jane Massie; Katherine N DuHamel
Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae.
The breast journal 2013;19(3):285-92.
2013: Paul K Newton; Jorge Nieva; Larry Norton; Lyudmila Bazhenova; Kelly Bethel; Jeremy Mason; Peter Kuhn
Spreaders and sponges define metastasis in lung cancer: a markov chain monte carlo mathematical model.
Cancer research 2013;73(9):2760-9.
2012: Elizabeth Comen; Patrick G Morris; Larry Norton
Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer.
Journal of mammary gland biology and neoplasia 2012;17(3-4):241-9.
2012: Lawrence N Shulman; Eric P Winer; James N Atkins; Heather P Becker; Donald A Berry; Constance Cirrincione; Gretchen Kimmick; Silvana Martino; Erica Mayer; Hyman Muss; Larry Norton; Ruth O'Regan; Edith A Perez; Charles J Schneider; Clifford Hudis
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(33):4071-6.
2012: Yong H Wen; Zhaoshi Zeng; Muzaffar Akram; Edi Brogi; Jeff Catalano; Larry Norton; Philip B Paty; Jinru Shia
DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
The American journal of surgical pathology 2012;36(11):1700-8.
2012: Clifford A Hudis; Hy Muss; Larry Norton; Marc L Citron; Eric P Winer
Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(25):3148-9; author reply 3149-50.
2012: Zsofia Kinga Stadler; Joseph Vijai; Michael Wigler; Boris Yamrom; Rohini Rau-Murthy; Mark Robson; Michael Ronemus; Kara Sarrel; Kasmintan Schrader; Sohela Shah; Joel Sheinfeld; George Bosl; Diane Esposito; Darren Feldman; Nichole Hansen; Noah D Kauff; Jude Kendall; Robert J Klein; Yoon-Ha Lee; Anthony Leotta; Dan Levy; Steven M Lipkin; Rajmohan Murali; Larry Norton; Kenneth Offit
Rare de novo germline copy-number variation in testicular cancer.
American journal of human genetics 2012;91(2):379-83.
2012: Yong Hannah Wen; Muzaffar Akram; Robert Benezra; Jeff Catalano; Anne Eaton; Alice Ho; Larry Norton; Sujata Patil; Edi Brogi
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Breast cancer research and treatment 2012;135(1):93-102.
2012: Swarnali Acharyya; Edi Brogi; Nancy Hogg; Juliet Kim; Margaret Leversha; Srinivas Malladi; Katia Manova-Todorova; Patrick G Morris; Larry Norton; Thordur Oskarsson; Venkatraman E Seshan; Sakari Vanharanta; Joan Massagué
A CXCL1 paracrine network links cancer chemoresistance and metastasis.
Cell 2012;150(1):165-78.
2012: Harold J Burstein; Gabriel N Hortobagyi; Kathy S Albain; Larry Norton; Edith A Perez; Martine J Piccart-Gebhart; Eric P Winer; Norman Wolmark; Clifford A Hudis
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(18):2179-82.
2012: Rebecca Waitz; Marcella Fassò; Larry Norton; Elena N Petre; Stephen B Solomon; Anne E Trumble; James P Allison
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.
Cancer research 2012;72(2):430-9.
2012: Elizabeth Comen; Larry Norton
Self-seeding in cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2012;195():13-23.
2011: Heather L McArthur; Patrick G Morris; Larry Norton; Sujata Patil; Jane Howard; Lindsay M Jacks; Kathleen M Mahoney; Clifford A Hudis
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
Cancer 2011;117(24):5461-8.
2011: Monica Fornier; Teresa A Gilewski; A Abbruzzi; Jacqueline F Bromberg; J Chang; Gabriella D'Andrea-Carlino; Chau Dang; Maura Dickler; S Modi; P G Morris; Larry Norton; Andrew D Seidman; Nancy T Sklarin; Clifford Hudis
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(12):2575-81.
2011: Ayca Gucalp; Clifford Hudis; Joan Massague; Larry Norton; Sujata Patil; Christine Pellegrino; Jean Santamauro; Joseph A Sparano; Maria Theodoulou-Haber; Alyson Abbruzzi; Jackie Bromberg; James Caravelli; Chau Dang; Tiffany A Traina
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Clinical breast cancer 2011;11(5):306-11.
2011: Devika Gajria; Stephanie Geneus; Clifford A Hudis; Larry Norton; Sujata Patil; Lee K Tan; Maria Theodoulou-Haber; Kimberly Feigin; Tiffany A Traina
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Cancer 2011;117(18):4125-31.
2011: Zvi Granot; Erik Henke; Tari A King; Larry Norton; Elizabeth A Comen; Robert Benezra
Tumor entrained neutrophils inhibit seeding in the premetastatic lung.
Cancer cell 2011;20(3):300-14.
2011: Larry Norton
Tumor self-seeding in breast cancer.
Clinical advances in hematology & oncology : H&O 2011;9(7):541-2.
2011: Elizabeth Comen; Larry Norton; Joan Massagué
Clinical implications of cancer self-seeding.
Nature reviews. Clinical oncology 2011;8(6):369-77.
2011: Patrick G Morris; Carol Chen; Richard Steingart; Martin Fleisher; Nancy Lin; Beverly Moy; Steven Come; Steven Sugarman; Alyson Abbruzzi; Robert Lehman; Sujata Patil; Maura Dickler; Heather L McArthur; Eric Winer; Larry Norton; Clifford A Hudis; Chau Dang
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(10):3490-9.
2011: Fang Fang; Sevin Turcan; Andreas Rimner; Andrew Kaufman; Dilip Giri; Luc G T Morris; Ronglai Shen; Venkatraman Seshan; Qianxing Mo; Adriana Heguy; Stephen B Baylin; NITA AHUJA; Agnes Viale; Joan Massague; Larry Norton; Linda Vahdat; Mary Ellen Moynahan; Timothy Chan
Breast cancer methylomes establish an epigenomic foundation for metastasis.
Science translational medicine 2011;3(75):75ra25.
2011: Christine A Wynveen; Tatjana Nehhozina; MUZAFFAR M AKRAM; Mohammed Hassan; Larry Norton; Kimberly Van Zee; Edi Brogi
Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up.
The American journal of surgical pathology 2011;35(1):1-14.
2010: Pamela Drullinsky; Steven M Sugarman; Monica N Fornier; Gabriella D'Andrea-Carlino; Teresa Gilewski; Diana Lake; Tiffany Traina; Carolyn Wasserheit-Lieblich; Nancy Sklarin; Deena Atieh-Graham; Nancy Mills; Tiffany Troso-Sandoval; Andrew D Seidman; Jeffrey Yuan; Hamangi Patel; Sujata Patil; Larry Norton; Clifford Hudis
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
Clinical breast cancer 2010;10(6):440-4.
2010: Clifford Hudis; Tiffany A Traina; Larry Norton
Capecitabine dosing is not yet optimized for breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(11):2291; author reply 2291-2.
2010: Chau Dang; Nancy Lin; Beverly Moy; Steven Come; Steven Sugarman; Patrick Morris; Alyson Abbruzzi; Carol Chen; Richard M Steingart; Sujata M Patil; Larry Norton; Eric Winer; Clifford Hudis
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(18):2982-8.
2010: Patrick G Morris; Heather L McArthur; Clifford Hudis; Larry Norton
Dose-dense chemotherapy for breast cancer: what does the future hold?
Future oncology (London, England) 2010;6(6):951-65.
2010: David J Gallagher; Mia M. Gaudet; Prodipto Pal; Tomas Kirchhoff; Lisa Balistreri; Kinjal Vora; Jasmine Bhatia; Zsofia Kinga Stadler; Samson W Fine; Victor E Reuter; Michael J Zelefsky; Michael J Morris; Howard I Scher; Robert J. Klein; Larry Norton; James A Eastham; Peter T Scardino; Mark Robson; Kenneth Offit
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(7):2115-21.
2010: Lawrence Marks; Constance Cirrincione; Thomas J Fitzgerald; Fran Laurie; Arvin S Glicksman; James Vredenburgh; Leonard R Prosnitz; Elizabeth J Shpall; Michael Crump; Paul G Richardson; Michael W Schuster; Jinli Ma; Bercedis L Peterson; Larry Norton; Steven Seagren; I Craig Henderson; David D Hurd; William P Peters
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
International journal of radiation oncology, biology, physics 2010;76(5):1305-13.
2010: Tiffany A Traina; Hope S Rugo; James Caravelli; Sujata M Patil; Benjamin Yeh; Michele E Melisko; John W Park; Stephanie Geneus; Matthew Paulson; Jill Grothusen; Andrew D Seidman; Monica Fornier; Diana E Lake; Chau Dang; Mark Robson; Maria Theodoulou-Haber; Carlos D Flombaum; Larry Norton; Clifford Hudis; Maura Dickler
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):628-33.
2010: Sarat Chandarlapaty; M Scaltriti; P Angelini; Q Ye; M Guzman; Clifford Hudis; Larry Norton; David B Solit; Joaquín Arribas; José Baselga; Neal Rosen
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
Oncogene 2010;29(3):325-34.
2010: Tiffany A Traina; Ute Dugan; Brian Higgins; Kenneth Kolinsky; Maria Theodoulou-Haber; Clifford A Hudis; Larry Norton
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.
Breast disease 2010;31(1):7-18.
2009: Mi-Young Kim; Thordur Oskarsson; Swarnali Acharyya; Don X Nguyen; Xiang H-F Zhang; Larry Norton; Joan Massagué
Tumor self-seeding by circulating cancer cells.
Cell 2009;139(7):1315-26.
2009: Patrick G Morris; Maura Dickler; Heather L McArthur; Tiffany A Traina; Steven Sugarman; Nancy Lin; Beverly Moy; Steven Come; Laura Godfrey; Benjamin Nulsen; Carol Chen; Richard M Steingart; Hope S Rugo; Larry Norton; Eric Winer; Clifford Hudis; Chau Dang
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):6117-23.
2009: Luca Gianni; Larry Norton; Norman Wolmark; Thomas M Suter; Gianni Bonadonna; Gabriel N Hortobagyi
Role of anthracyclines in the treatment of early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4798-808.
2009: Tomas Kirchhoff; Zhang-qun Chen; Bert Gold; Prodipto Pal; Mia M. Gaudet; Kristi Kosarin; Douglas A Levine; Peter Gregersen; Sara Spencer; Megan Harlan; Mark Robson; Robert J. Klein; Clifford Hudis; Larry Norton; Michael Dean; Kenneth Offit
The 6q22.33 locus and breast cancer susceptibility.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(9):2468-75.
2009: Xiang H-F Zhang; Qiongqing Wang; William Gerald; Clifford Hudis; Larry Norton; Marcel Smid; John A Foekens; Joan Massagué
Latent bone metastasis in breast cancer tied to Src-dependent survival signals.
Cancer cell 2009;16(1):67-78.
2009: Steven Sugarman; Carolyn Wasserheit; Elizabeth Hodgman; Maryellen Coglianese; Anne D'Alassandro; Monica Fornier; Monica Fournier; Tiffany Troso-Sandoval; Gabriella D'Andrea-Carlino; P Drullinsky; Diana E Lake; Roshini George; Nancy Mills; Mary Ellen Moynahan; Joyce Smith; Katherine S Panageas; Larry Norton; Clifford Hudis
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Breast cancer research and treatment 2009;115(3):609-12.
2009: Hyman Muss; Donald A Berry; Constance Cirrincione; Maria Theodoulou-Haber; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn Dressler; Harvey J Cohen; Heather P Becker; Patricia A Kartcheske; Judith D Wheeler; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Gustav Magrinat; Gutav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Larry Norton; Clifford Hudis; Eric P Winer
Adjuvant chemotherapy in older women with early-stage breast cancer.
The New England journal of medicine 2009;360(20):2055-65.
2009: G G Kimmick; C Cirrincione; D B Duggan; Kapil N Bhalla; N Robert; D Berry; Larry Norton; S Lemke; I C Henderson; Clifford Hudis; E Winer
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
Breast cancer research and treatment 2009;113(3):479-90.
2008: Maura Dickler; Hope S Rugo; Carey A Eberle; Edi Brogi; James Caravelli; Katherine S Panageas; Jeff Boyd; Benjamin Yeh; Diana E Lake; Chau Dang; Teresa A Gilewski; Jacqueline F Bromberg; Andrew D Seidman; Gabriella D'Andrea-Carlino; Mark M Moasser; Michele Melisko; John W Park; Janet Dancey; Larry Norton; Clifford Hudis
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7878-83.
2008: Chau Dang; Gabriella D'Andrea-Carlino; Diana E Lake; Steve Sugarman; Monica Fornier; Mary Ellen Moynahan; Teresa A Gilewski; Arti Hurria; Nancy Mills; Tiffany Troso-Sandoval; Roshini George; Mark Robson; Maura Dickler; Karen Smith; Katherine S Panageas; Larry Norton; Clifford Hudis
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
Clinical breast cancer 2008;8(5):418-24.
2008: Tiffany A Traina; Italo POggesi; Mark Robson; A Asnis; B A Duncan; Alexandra S Heerdt; Chau Dang; Diana E Lake; Mark M Moasser; Katherine S Panageas; Patrick I Borgen; Larry Norton; Clifford Hudis; Maura Dickler
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Breast cancer research and treatment 2008;111(2):377-88.
2008: Chau Dang; Larry Norton; Clifford Hudis
Dose-dense chemotherapy with trastuzumab is an appropriate option.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3655-6; author reply 3656.
2008: Blase N Polite; Constance Cirrincione; Gini F Fleming; Donald A Berry; Andrew D Seidman; Hyman Muss; Larry Norton; Charles Shapiro; Kamal Bakri; Paul Kelly Marcom; Diana Lake; Joel H Schwartz; Clifford Hudis; Eric P Winer
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2659-65.
2008: Michael P DiGiovanna; David F Stern; Susan M Edgerton; Gloria Broadwater; Lynn Dressler; Daniel R Budman; I Craig Henderson; Larry Norton; Edison Liu; Hyman Muss; Donald A Berry; Daniel F Hayes; Ann D Thor
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2364-72.
2008: James N Ingle; Dongsheng Tu; Joseph L Pater; Hyman Muss; Silvana Martino; Nicholas J Robert; Martine J Piccart; M Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Paul E Goss
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(5):877-82.
2008: Minetta C Liu; George D Demetri; Donald A Berry; Larry Norton; Gloria Broadwater; Nicholas J Robert; David Duggan; Daniel F Hayes; I Craig Henderson; Alan Lyss; Judith Hopkins; Peter A Kaufman; Paul Kelly Marcom; Jerry Younger; Nancy U Lin; Katherine Tkaczuk; Eric P Winer; Clifford Hudis
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Cancer treatment reviews 2008;34(3):223-30.
2008: Paul E Goss; James N Ingle; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Dongsheng Tu
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1948-55.
2008: Tiffany A Traina; Maria Theodoulou-Haber; Kimberly Feigin; Sujata M Patil; K Lee Tan; Charles Edwards; Ute Dugan; Larry Norton; Clifford Hudis
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1797-802.
2008: Lee K Tan; Dilip D Giri; Amanda J Hummer; Katherine S Panageas; Edi Brogi; Larry Norton; Clifford Hudis; Patrick I Borgen; Hiram S Cody
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1803-9.
2008: Andrew D Seidman; Donald Berry; Constance Cirrincione; Lyndsay Harris; Hyman Muss; Paul Kelly Marcom; Grandella Gipson; Harold J Burstein; Diana E Lake; Charles L Shapiro; Peter Ungaro; Larry Norton; Eric Winer; Clifford Hudis
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1642-9.
2008: Mary Morrogh; Anna Park; Larry Norton; Tari A King
Changing indications for surgery in patients with stage IV breast cancer: a current perspective.
Cancer 2008;112(7):1445-54.
2008: Bert Gold; Tomas Kirchhoff; Stefan Stefanov; James Lautenberger; Agnes Viale; Judy E Garber; Eitan Friedman; steven narod; Adam B Olshen; Peter Gregersen; Kristi Kosarin; Adam Olsh; Julie Bergeron; Nathan Ellis; Robert J. Klein; andrew clark; Larry Norton; Michael Dean; Jeff Boyd; Kenneth Offit
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(11):4340-5.
2008: Chau Dang; Monica Fornier; Steven Sugarman; Tiffany Troso-Sandoval; Diana E Lake; Gabriella D'Andrea-Carlino; Andrew D Seidman; Nancy T Sklarin; Maura Dickler; Violante E Currie; Teresa A Gilewski; Mary Ellen Moynahan; P Drullinsky; Mark Robson; Carolyn Wasserheit-Leiblich; Nancy Mills; Richard M Steingart; Katherine S Panageas; Larry Norton; Clifford Hudis
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1216-22.
2008: Noah D Kauff; Susan M Domchek; Tara M Friebel; Mark Robson; Johanna Lee; Judy E Garber; Claudine Isaacs; D Gareth Evans; Henry Lynch; Rosalind A Eeles; Susan L Neuhausen; Mary B Daly; Ellen Matloff; Joanne L Blum; Paul Sabbatini; Richard R Barakat; Clifford Hudis; Larry Norton; Kenneth Offit; Timothy R Rebbeck
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1331-7.
2008: Larry Norton
Cancer stem cells, self-seeding, and decremented exponential growth: theoretical and clinical implications.
Breast disease 2008;29():27-36.
2008: Adam B Olshen; Bert Gold; Kirk E Lohmueller; Jeffery Struewing; Jaya M Satagopan; Stefan A Stefanov; Eleazar Eskin; Tomas Kirchhoff; James A Lautenberger; Robert J. Klein; Eitan Friedman; Larry Norton; Nathan Ellis; Agnes Viale; Catherine S Lee; Patrick I Borgen; andrew clark; Kenneth Offit; Jeff Boyd
Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping.
BMC genetics 2008;9():14.
2008: Sarat Chandarlapaty; Ayana Sawai; Qing Ye; Anisa Scott; Melanie Silinski; Ken Huang; Pat Fadden; Jeff Partdrige; Steven Hall; Paul Steed; Larry Norton; Neal Rosen; David B Solit
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):240-8.
2007: Shanu Modi; Alison T Stopeck; Michael S Gordon; David Mendelson; David B Solit; Rochelle Bagatell; Weining Ma; Jennifer Wheler; Neal Rosen; Larry Norton; Gillian F Cropp; Robert G Johnson; Alison L Hannah; Clifford Hudis
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5410-7.
2007: Larry Norton
Tumor dormancy: separating observations from experimental science.
Nature clinical practice. Oncology 2007;4(12):671.
2007: Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter M Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5287-312.
2007: Francesca Orlandi; Franco Maria Venanzi; Antonio Concetti; Hanako Yamauchi; Shakuntala Tiwari; Larry Norton; Jedd D Wolchok; Alan N Houghton; Polly D Gregor
Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6195-203.
2007: Daniel F Hayes; Ann D Thor; Lynn Dressler; Donald Weaver; Susan M Edgerton; David Cowan; Gloria Broadwater; Lori J Goldstein; Silvana Martino; James N Ingle; I Craig Henderson; Larry Norton; Eric P Winer; Clifford Hudis; Matthew J Ellis; Donald A Berry
HER2 and response to paclitaxel in node-positive breast cancer.
The New England journal of medicine 2007;357(15):1496-506.
2007: Tari A King; Weiwei Li; Edi Brogi; Cindy J Yee; Mary L Gemignani; Narciso Olvera; Douglas A Levine; Larry Norton; Mark Robson; Kenneth Offit; Patrick I Borgen; Jeff Boyd
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
Annals of surgical oncology 2007;14(9):2510-8.
2007: Hyman Muss; Donald A Berry; Constance Cirrincione; Daniel R Budman; I Craig Henderson; Marc L Citron; Larry Norton; Eric P Winer; Clifford Hudis
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3699-704.
2007: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2006-11.
2007: Teresa A Gilewski; Govind Ragupathi; Maura Dickler; Shemeeakah Powell; Sonal Bhuta; Katherine S Panageas; R Rao Koganty; Jeannette Chin-Eng; Clifford Hudis; Larry Norton; Alan N Houghton; Philip O Livingston
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2977-85.
2007: Martine Piccart; Aron Goldhirsch; William Wood; Kathleen Pritchard; José Baselga; Linda Reaby; Ingrid Kössler; Stella Kyriakides; Larry Norton; Alan Coates
Keeping faith with trial volunteers.
Nature 2007;446(7132):137-8.
2007: Monica Fornier; Andrew D Seidman; Diana E Lake; Gabriella D'Andrea-Carlino; Jacqueline F Bromberg; Mark Robson; Catherine Van Poznak; Katherine S Panageas; Marietta Atienza; Larry Norton; Clifford Hudis
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):223-7.
2006: James Hicks; Alexander Krasnitz; B Lakshmi; Nicholas Navin; Michael Riggs; Evan Leibu; Diane Esposito; Joan Alexander; Jennifer Troge; Vladimir Grubor; Seungtai Yoon; Michael Wigler; Kenny Ye; Anne-Lise Børresen-Dale; Bjørn Naume; Ellen Schlicting; Larry Norton; Torsten Hägerström; Lambert Skoog; Gert Auer; Susanne Månér; Pär Lundin; Anders Zetterberg
Novel patterns of genome rearrangement and their association with survival in breast cancer.
Genome research 2006;16(12):1465-79.
2006: Mercedes Rincon; Gloria Broadwater; Lyndsay Harris; Abigail Crocker; Donald Weaver; Lynn Dressler; Donald Berry; Linda Sutton; Richard Michaelson; Michael Messino; Jeffrey Kirshner; Gini Fleming; Eric P Winer; Clifford Hudis; Stacy Appel; Larry Norton; Hyman Muss
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Breast cancer research and treatment 2006;100(3):301-8.
2006: Tiffany A Traina; Larry Norton; Karen Drucker; Bhuvanesh Singh
Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.
The oncologist 2006;11(10):1070-1.
2006: Arti Hurria; Mark T Fleming; Sharyn D Baker; W Kevin Kelly; Katie Cutchall; Katherine S Panageas; James Caravelli; Henry Yeung; Mark G Kris; Jorge Gomez; Vincent A Miller; Gabriella D'Andrea-Carlino; Howard I Scher; Larry Norton; Clifford Hudis
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6100-5.
2006: James N Ingle; Dongsheng Tu; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Paul E Goss
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Breast cancer research and treatment 2006;99(3):295-300.
2006: Shanu Modi; Gabriella D'Andrea-Carlino; Larry Norton; Tzy-Jyun Yao; James Caravelli; Peter P Rosen; Clifford Hudis; Andrew D Seidman
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
Clinical breast cancer 2006;7(3):270-7.
2006: Richard Simon; Larry Norton
The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.
Nature clinical practice. Oncology 2006;3(8):406-7.
2006: Larry Norton; Joan Massagué
Is cancer a disease of self-seeding?
Nature medicine 2006;12(8):875-8.
2006: Arti Hurria; Shari Goldfarb; Carol Rosen; Jimmie C Holland; Enid Zuckerman; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea-Carlino; Mark M Moasser; Chau Dang; Catherine Van Poznak; Mark Robson; Violante E Currie; Maria Theodoulou-Haber; Larry Norton; Clifford Hudis
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
Breast cancer research and treatment 2006;98(3):343-8.
2006: Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman Muss; Larry Norton; Clifford Hudis; Eric P Winer
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
JAMA : the journal of the American Medical Association 2006;295(14):1658-67.
2006: Larry Norton
Use of dose-dense chemotherapy in the management of breast cancer.
Clinical advances in hematology & oncology : H&O 2006;4(1):36-7.
2006: Catherine Van Poznak; Simon Cross; M Saggese; Clifford Hudis; Katherine S Panageas; Larry Norton; Robert E Coleman; Ingunn Holen
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Journal of clinical pathology 2006;59(1):56-63.
2006: Nathan Ellis; Tomas Kirchhoff; Nandita Mitra; Tian-Zhang Ye; Shaokun Chuai; Helen Huang; Khedoudja Nafa; Larry Norton; Susan L Neuhausen; Derek Gordon; Jeffery Struewing; Steven A Narod; Kenneth Offit
Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping.
Genetic epidemiology 2006;30(1):48-61.
2005: Larry Norton
Society for Integrative Oncology First International Conference, New York City, November 2004. Keynote address.
Journal of the Society for Integrative Oncology 2005;3(4):121-3.
2005: Carmen Tornos; Robert A Soslow; Shirley Chen; MUZAFFAR M AKRAM; Amanda J Hummer; Nadeem R Abu-Rustum; Larry Norton; Lee K Tan
Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
The American journal of surgical pathology 2005;29(11):1482-9.
2005: Monica Fornier; Shanu Modi; Katherine S Panageas; Larry Norton; Clifford Hudis
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
Cancer 2005;104(8):1575-9.
2005: Noah D Kauff; Nandita Mitra; Mark Robson; Karen E Hurley; Shaokun Chuai; Deborah Goldfrank; Eve A Wadsworth; Johanna Lee; Tessa Cigler; Patrick I Borgen; Larry Norton; Richard R Barakat; Kenneth Offit
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Journal of the National Cancer Institute 2005;97(18):1382-4.
2005: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Journal of the National Cancer Institute 2005;97(17):1262-71.
2005: Kathryn Beal; Clifford Hudis; Larry Norton; Raquel Wagman; Beryl Mc Cormick
Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
The breast journal 2005;11(5):317-20.
2005: Lynn Dressler; Donald A Berry; Gloria Broadwater; David Cowan; Kelly Cox; Stephanie Griffin; Ashley Miller; Jessica Tse; Debra Novotny; Diane L Persons; Maurice Barcos; I Craig Henderson; Edison Liu; Ann D Thor; Daniel R Budman; Hyman Muss; Larry Norton; Daniel F Hayes
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(19):4287-97.
2005: Arti Hurria; Kelly Brogan; Katherine S Panageas; Carol Pearce; Larry Norton; Ann Jakubowski; Marjorie Zauderer; Jane Howard; Clifford Hudis
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Breast cancer research and treatment 2005;92(2):151-6.
2005: Larry Norton
Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.
The oncologist 2005;10(6):370-81.
2005: Shanu Modi; Violante E Currie; Andrew D Seidman; Ariadne M Bach; Katherine S Panageas; Maria Theodoulou-Haber; Mark M Moasser; Gabriella D'Andrea-Carlino; Diana E Lake; Jennifer Choi; Larry Norton; Clifford Hudis
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Clinical breast cancer 2005;6(1):55-60.
2005: William P Peters; Gary Rosner; James J Vredenburgh; Elizabeth J Shpall; Michael Crump; Paul G Richardson; Michael W Schuster; Lawrence Marks; Constance Cirrincione; Larry Norton; I Craig Henderson; Richard L Schilsky; David D Hurd
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2191-200.
2005: Hyman Muss; Susan Woolf; Donald Berry; Constance Cirrincione; Raymond B Weiss; Daniel R Budman; William C Wood; I Craig Henderson; Clifford Hudis; Eric P Winer; Harvey Cohen; Judith Wheeler; Larry Norton
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
JAMA : the journal of the American Medical Association 2005;293(9):1073-81.
2005: Shanu Modi; Andrew D Seidman; Maura Dickler; Mark M Moasser; Gabriella D'Andrea-Carlino; Mary Ellen Moynahan; Jennifer H Menell; Katherine S Panageas; Lee K Tan; Larry Norton; Clifford Hudis
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Breast cancer research and treatment 2005;90(2):157-63.
2005: Monica Fornier; Andrew D Seidman; Morton K Schwartz; F Ghani; Robert P Thiel; Larry Norton; Clifford Hudis
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(2):234-9.
2005: Shanu Modi; Michael P DiGiovanna; Zhao Lu; Chaya S Moskowitz; Katherine S Panageas; Catherine Van Poznak; Clifford Hudis; Larry Norton; Lee Tan; David F Stern; Darryl L Carter; Andrew D Seidman
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Cancer investigation 2005;23(6):483-7.
2005: Arti Hurria; Anju Hurria; Kelly Brogan; Katherine S Panageas; Carol Pearce; Larry Norton; Ann Jakubowski; Jane Howard; Clifford Hudis
Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
Drugs & aging 2005;22(9):785-91.
2005: Arti Hurria; Kelly Brogan; Katherine S Panageas; Ann Jakubowski; Marjorie Zauderer; Carol Pearce; Larry Norton; Jane Howard; Clifford Hudis
Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Drugs & aging 2005;22(8):709-15.
2005: Monica Fornier; Larry Norton
Dose-dense adjuvant chemotherapy for primary breast cancer.
Breast cancer research : BCR 2005;7(2):64-9.
2005: Andrew D Seidman; Larry Norton
Two regimens of docetaxel for metastatic breast cancer.
Current oncology reports 2005;7(1):7.
2005: Mark Robson; Tiffany Svahn; Beryl Mc Cormick; Patrick I Borgen; Clifford Hudis; Larry Norton; Kenneth Offit
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Cancer 2005;103(1):44-51.
2005: Carolyn I Sartor; Bercedis L Peterson; Susan Woolf; Thomas J Fitzgerald; Fran Laurie; Andrew J Turrisi; Jeffrey A. Bogart; I Craig Henderson; Larry Norton
Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):30-40.
2004: Michael W Kattan; Dilip D Giri; Katherine S Panageas; Amanda J Hummer; Milicent Cranor; Kimberly Van Zee; Clifford Hudis; Larry Norton; Patrick I Borgen; Lee K Tan
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy.
Cancer 2004;101(11):2509-15.
2004: Carol S Portlock; Jing Qin; P Schaindlin; Nancy Roistacher; J Myers; Daniel A Filippa; Diane C Louie; Andrew D Zelenetz; JP O'Brien; Craig Moskowitz; Larry Norton; Joachim Yahalom; David J Straus; Joseph R Bertino
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(10):1495-503.
2004: Kevin S Hughes; Lauren A Schnaper; Donald Berry; Constance Cirrincione; Beryl Mc Cormick; Brenda Shank; Judith Wheeler; Lorraine A Champion; Thomas J Smith; Barbara L Smith; Charles Shapiro; Hyman Muss; Eric P Winer; Clifford Hudis; William Wood; David Sugarbaker; I Craig Henderson; Larry Norton
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
The New England journal of medicine 2004;351(10):971-7.
2004: Chau Dang; Gabriella D'Andrea-Carlino; Mary Ellen Moynahan; Maura Dickler; Andrew D Seidman; Monica Fornier; Mark Robson; Maria Theodoulou-Haber; Diana E Lake; Violante E Currie; Arti Hurria; Katherine S Panageas; Larry Norton; Clifford Hudis
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5754-61.
2004: Tari A King; Archana Ganaraj; Jane V Fey; Lee K Tan; Clifford Hudis; Larry Norton; Hiram S Cody; Patrick I Borgen
Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy.
Cancer 2004;101(5):926-33.
2004: Chau Dang; Andrew J Dannenberg; Kotha Subbaramaiah; Maura Dickler; Mark M Moasser; Andrew D Seidman; Gabriella D'Andrea-Carlino; Maria Theodoulou-Haber; Katherine S Panageas; Larry Norton; Clifford Hudis
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4062-7.
2004: Eric P Winer; Donald A Berry; Susan Woolf; David B Duggan; Alice B Kornblith; Lyndsay N Harris; Richard A Michaelson; Jeffrey A Kirshner; Gini F Fleming; Michael C Perry; Mark Graham II; Stewart A Sharp; Roger Keresztes; I Craig Henderson; Clifford Hudis; Hyman Muss; Larry Norton
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2061-8.
2004: Gretchen Kimmick; Mark J Ratain; Don Berry; Susan Woolf; Larry Norton; Hyman Muss
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
Investigational new drugs 2004;22(1):83-9.
2004: Mark Robson; Pierre O Chappuis; Jaya M Satagopan; Nora Wong; Jeff Boyd; John R Goffin; Clifford Hudis; David Roberge; Larry Norton; Louis R Bégin; Kenneth Offit; William D Foulkes
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Breast cancer research : BCR 2004;6(1):R8-R17.
2003: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; Patrick Therasse; Michael J Palmer; Joseph L Pater
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
The New England journal of medicine 2003;349(19):1793-802.
2003: Kenneth Offit; Orna Levran; Brian Mullaney; Katherine Mah; Khedoudja Nafa; Sat Dev Batish; Raffaella Diotti; Hildegard Schneider; Amie M Deffenbaugh; Thomas Scholl; Virginia K Proud; Mark Robson; Larry Norton; Nathan Ellis; Helmut Hanenberg; Arleen D Auerbach
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.
Journal of the National Cancer Institute 2003;95(20):1548-51.
2003: Robert Lucito; John Healy; Joan Alexander; Andrew Reiner; Diane Esposito; Maoyen Chi; Linda Rodgers; Amy Brady; Jonathan Sebat; Jennifer Troge; Joseph A West; Seth Rostan; Ken Nguyen; Scott Powers; Kenny Ye; Adam B Olshen; Venkatraman E Seshan; Larry Norton; Michael Wigler
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation.
Genome research 2003;13(10):2291-305.
2003: Arti Hurria; Denis Leung; Kathleen Trainor; Larry Norton; Clifford Hudis
Screening chest imaging studies are not effective in the follow-up of breast cancer patients.
The Journal of oncology management : the official journal of the American College of Oncology Administrators 2003;12(5):13-5.
2003: Alice B Kornblith; James E Herndon; Raymond B Weiss; Chunfeng Zhang; Enid Zuckerman; Sylvia Rosenberg; Magriet Mertz; David Payne; Mary Jane Massie; James F Holland; Patti Wingate; Larry Norton; Jimmie C Holland
Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy.
Cancer 2003;98(4):679-89.
2003: Raymond B Weiss; Susan H Woolf; Erin P Demakos; James F Holland; Donald A Berry; Geoffrey Falkson; Constance Cirrincione; Alice Robbins; Sandra Bothun; I Craig Henderson; Larry Norton
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1825-35.
2003: Howard L Parnes; Constance Cirrincione; Joseph Aisner; Donald A Berry; Steven Allen; Jeffrey Abrams; E Chuang; M Robert Cooper; Michael C Perry; David B Duggan; T P Szatrowski; I Craig Henderson; Larry Norton
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1819-24.
2003: Arti Hurria; Denis Leung; Kathleen Trainor; Patrick I Borgen; Larry Norton; Clifford Hudis
Factors influencing treatment patterns of breast cancer patients age 75 and older.
Critical reviews in oncology/hematology 2003;46(2):121-6.
2003: Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David D Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman Muss; Larry Norton
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1431-9.
2003: I Craig Henderson; Donald A Berry; George D Demetri; Constance Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman Muss; Larry Norton
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):976-83.
2002: Shanu Modi; Katherine S Panageas; Elaine T Duck; Ariadne M Bach; Nancy Weinstock; James Dougherty; Laura D Cramer; Clifford Hudis; Larry Norton; Andrew D Seidman
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3665-73.
2002: Kotha Subbaramaiah; Larry Norton; William Gerald; Andrew J Dannenberg
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.
The Journal of biological chemistry 2002;277(21):18649-57.
2002: Noah D Kauff; Jaya M Satagopan; Mark Robson; Lauren Scheuer; Martee Hensley; Clifford Hudis; Nathan Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
The New England journal of medicine 2002;346(21):1609-15.
2002: Jose Baselga; Larry Norton
Focus on breast cancer.
Cancer cell 2002;1(4):319-22.
2002: Catherine Van Poznak; Lee Tan; Katherine S Panageas; Crispinita D Arroyo; Clifford Hudis; Larry Norton; Andrew D Seidman
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2319-26.
2002: Lauren Scheuer; Noah D Kauff; Mark Robson; Bridget Kelly; Richard R Barakat; Jaya M Satagopan; Nathan Ellis; Martee Hensley; Jeff Boyd; Patrick I Borgen; Larry Norton; Kenneth Offit
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1260-8.
2002: Donald A Berry; Gloria Broadwater; John P Klein; Karen Antman; Joseph Aisner; Jacob Bitran; Mary Costanza; Cesar O Freytes; Edward A Stadtmauer; Robert Peter Gale; I Craig Henderson; Hillard M Lazarus; Philip L McCarthy; Larry Norton; Howard L Parnes; Andrew L Pecora; Michael C Perry; Philip Rowlings; Gary Spitzer; Mary M Horowitz
High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):743-50.
2002: Anthony J Guidi; Donald A Berry; Gloria Broadwater; Birgit Helmchen; Ira J Bleiweiss; Daniel R Budman; I Craig Henderson; Larry Norton; Daniel F Hayes
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):732-42.
2001: Maura Dickler; Larry Norton
The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
Annals of the New York Academy of Sciences 2001;949():134-42.
2001: Monica Fornier; Andrew D Seidman; Maria Theodoulou-Haber; Mary Ellen Moynahan; Violante E Currie; Mark M Moasser; Nancy T Sklarin; Teresa A Gilewski; Gabriella D'Andrea-Carlino; R Salvaggio; Katherine S Panageas; Larry Norton; Clifford Hudis
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3934-41.
2001: Daniel F Hayes; H Yamauchi; Gloria Broadwater; Constance Cirrincione; S P Rodrigue; Donald A Berry; J Younger; L L Panasci; F Millard; D B Duggan; Larry Norton; I Craig Henderson
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2703-11.
2001: Pamela N Münster; Andrea Basso; David B Solit; Larry Norton; Neal Rosen
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2228-36.
2001: Larry Norton
High-dose chemotherapy for breast cancer: "how do you know?".
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2769-70.
2001: Andrew D Seidman; Monica Fornier; Francisco J Esteva; Lee Tan; S Kaptain; Ariadne M Bach; Katherine S Panageas; Crispinita D Arroyo; V Valero; Violante E Currie; Teresa A Gilewski; Maria Theodoulou-Haber; Mary Ellen Moynahan; Mark M Moasser; Nancy T Sklarin; Maura Dickler; Gabriella D'Andrea-Carlino; M Cristofanilli; E Rivera; Gabriel N Hortobagyi; Larry Norton; Clifford Hudis
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2587-95.
2001: Catherine Van Poznak; Andrew D Seidman; MM Reidenberg; Mark M Moasser; Nancy T Sklarin; Kimberly Van Zee; Patrick I Borgen; Marc J Gollub; D Bacotti; Tzy-Jyun Yao; R Bloch; M Ligueros; M Sonenberg; Larry Norton; Clifford Hudis
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.
Breast cancer research and treatment 2001;66(3):239-48.
2001: Pamela N Münster; Aman U Buzdar; Kapil Dhingra; N Enas; L Ni; M Major; Allen S Melemed; Andrew D Seidman; Daniel J Booser; Richard Theriault; Larry Norton; Clifford Hudis
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2002-9.
2001: Dennis J Slamon; Brian Leyland-Jones; Steven Shak; H Fuchs; Virginia Paton; Alex Bajamonde; T Fleming; Wolfgang Eiermann; JM Wolter; Mark D Pegram; J Baselga; Larry Norton
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
The New England journal of medicine 2001;344(11):783-92.
2001: Teresa A Gilewski; Govind Ragupathi; S Bhuta; Linda J Williams; Cristina Musselli; XF Zhang; William G Bornmann; Maria A Spassova; K P Bencsath; Katherine S Panageas; J Chin; Clifford Hudis; Larry Norton; Alan N Houghton; Philip O Livingston; Samuel J Danishefsky
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(6):3270-5.
2001: Alice B Kornblith; James E Herndon; Enid Zuckerman; Catherine M Viscoli; R I Horwitz; M Robert Cooper; L Harris; Katherine Tkaczuk; M C Perry; Daniel R Budman; Larry Norton; Jimmie C Holland
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.
Cancer 2001;91(2):443-54.
2001: Larry Norton
Dose-intensity, dose-escalation, and dose-density in the adjuvant chemotherapy of primary, operable breast cancer.
Breast disease 2001;14():81-9.
2001: P N Munster; Larry Norton
Predictive factor for the response to adjuvant therapy with emphasis in breast cancer.
Breast cancer research : BCR 2001;3(6):361-4.
2001: Larry Norton
Theoretical concepts and the emerging role of taxanes in adjuvant therapy.
The oncologist 2001;6 Suppl 3():30-5.
2001: Jane A Cauley; Larry Norton; Marc Lippman; S Eckert; Kathryn A Krueger; D W Purdie; J Farrerons; A Karasik; D Mellstrom; K W Ng; J J Stepan; T J Powles; Monica Morrow; A Costa; S L Silfen; EL Walls; H Schmitt; D B Muchmore; V Craig Jordan; L G Ste-Marie
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Breast cancer research and treatment 2001;65(2):125-34.
2000: Robert Lucito; J West; Andrew Reiner; Joan Alexander; Diane Esposito; Bud Mishra; Scott Powers; Larry Norton; Michael Wigler
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations.
Genome research 2000;10(11):1726-36.
2000: Donald A Berry; Hyman Muss; Ann D Thor; Lynn Dressler; Edison Liu; Gloria Broadwater; Daniel R Budman; I Craig Henderson; Maurice Barcos; Daniel F Hayes; Larry Norton
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3471-9.
2000: Kotha Subbaramaiah; J C Hart; Larry Norton; Andrew J Dannenberg
Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways.
The Journal of biological chemistry 2000;275(20):14838-45.
2000: Teresa A Gilewski; S Adluri; Govind Ragupathi; S Zhang; Tzy-Jyun Yao; Katherine S Panageas; Mary Ellen Moynahan; Alan N Houghton; Larry Norton; Philip O Livingston
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1693-701.
2000: A J Guidi; D A Berry; Gloria Broadwater; M Perloff; Larry Norton; Maurice Barcos; Daniel F Hayes
Association of angiogenesis in lymph node metastases with outcome of breast cancer.
Journal of the National Cancer Institute 2000;92(6):486-92.
2000: Rachel B Hazan; G R Phillips; Rui F Qiao; Larry Norton; S A Aaronson
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis.
The Journal of cell biology 2000;148(4):779-90.
2000: José Baselga; David G Pfister; M Robert Cooper; R Cohen; B Burtness; M Bos; Gabriella D'Andrea-Carlino; Andrew D Seidman; Larry Norton; K Gunnett; J Falcey; V Anderson; Harlan W Waksal; John Mendelsohn
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):904-14.
2000: Teresa A Gilewski; Andrew D Seidman; Larry Norton; Clifford Hudis
An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S23-6.
2000: J M Donnelly; Alice B Kornblith; Stewart Fleishman; Enid Zuckerman; G Raptis; Clifford Hudis; N Hamilton; D Payne; Mary Jane Massie; Larry Norton; Jimmie C Holland
A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners.
Psycho-oncology 2000;9(1):44-56.
1999: Mark Robson; D Levin; Mark G Federici; Jaya M Satagopan; F Bogolminy; Alexandra S Heerdt; Patrick I Borgen; Beryl Mc Cormick; Clifford Hudis; Larry Norton; Jeff Boyd; Kenneth Offit
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Journal of the National Cancer Institute 1999;91(24):2112-7.
1999: José Baselga; Debu Tripathy; John Mendelsohn; S Baughman; C C Benz; L Dantis; Nancy T Sklarin; Andrew D Seidman; Clifford Hudis; J Moore; Paul Peter Rosen; T Twaddell; I Craig Henderson; Larry Norton
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Seminars in oncology 1999;26(4 Suppl 12):78-83.
1999: Steven R Cummings; S Eckert; Kathryn A Krueger; Deborah Grady; T J Powles; Jane A Cauley; Larry Norton; Thomas Nickelsen; N H Bjarnason; Monica Morrow; Marc Lippman; D Black; J E Glusman; A Costa; V Craig Jordan
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA : the journal of the American Medical Association 1999;281(23):2189-97.
1999: E G Levine; Constance Cirrincione; T P Szatrowski; George P Canellos; Larry Norton; I Craig Henderson
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study.
American journal of clinical oncology 1999;22(3):218-22.
1999: M E Costanza; Raymond B Weiss; I Craig Henderson; Larry Norton; Donald A Berry; Constance Cirrincione; Eric P Winer; William C Wood; E Frei; O R McIntyre; Richard L Schilsky
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1397-406.
1999: Clifford Hudis; Monica Fornier; L Riccio; David Lebwohl; John Crown; Teresa A Gilewski; A Surbone; Violante E Currie; Andrew D Seidman; B Reichman; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; Maria Theodoulou-Haber; L Weiselberg; R Salvaggio; Katherine S Panageas; Tzy-Jyun Yao; Larry Norton
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1118.
1999: Larry Norton
Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
Seminars in oncology 1999;26(1 Suppl 3):1-4.
1999: Larry Norton
Kinetic concepts in the systemic drug therapy of breast cancer.
Seminars in oncology 1999;26(1 Suppl 2):11-20.
1999: Gabriella D'Andrea-Carlino; DW Fennelly; Larry Norton; José Baselga; Teresa A Gilewski; Clifford Hudis; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; A Surbone; Maria Theodoulou-Haber; M A Templeton; Tzy-Jyun Yao; Andrew D Seidman
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):275-9.
1999: Clifford Hudis; Andrew D Seidman; José Baselga; G Raptis; David Lebwohl; Teresa A Gilewski; Mary Ellen Moynahan; Nancy T Sklarin; DW Fennelly; John Crown; A Surbone; M Uhlenhopp; Elyn Riedel; Tzy-Jyun Yao; Larry Norton
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):93-100.
1999: Jeffrey Abrams; Joseph Aisner; Constance Cirrincione; Donald A Berry; Hyman Muss; M Robert Cooper; I Craig Henderson; L Panasci; J Kirshner; J Ellerton; Larry Norton
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):64-73.
1998: Larry Norton
Breast cancer advocates in clinical research: a trialist's perspective.
Breast disease 1998;10(5-6):51-9.
1998: Andrew D Seidman; Clifford Hudis; J Albanell; J Albanel; William Tong; I Tepler; Violante E Currie; Mary Ellen Moynahan; Maria Theodoulou-Haber; Marc J Gollub; José Baselga; Larry Norton
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3353-61.
1998: Ann D Thor; Donald A Berry; Daniel R Budman; Hyman Muss; T Kute; I Craig Henderson; Maurice Barcos; Constance Cirrincione; Susan M Edgerton; C Allred; Larry Norton; Edison Liu
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
Journal of the National Cancer Institute 1998;90(18):1346-60.
1998: Daniel R Budman; Donald A Berry; Constance Cirrincione; I Craig Henderson; William C Wood; Raymond B Weiss; C R Ferree; Hyman Muss; Mark R Green; Larry Norton; E Frei
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.
Journal of the National Cancer Institute 1998;90(16):1205-11.
1998: José Baselga; Larry Norton; J Albanell; Y M Kim; John Mendelsohn
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
Cancer research 1998;58(13):2825-31.
1998: Susan Harlap; Ann G Zauber; D M Pollack; J Tang; A E Arena; P Sternfels; P Borgen; Larry Norton
Survival of premenopausal women with breast carcinoma: effects of menstrual timing of surgery.
Cancer 1998;83(1):76-88.
1998: Carol Aghajanian; DW Fennelly; F Shapiro; RJ Waltzman; Lois Almadrones; Catherine O'Flaherty; K O'Conner; Venkatraman E Seshan; Richard R Barakat; J Curtin; Carol L Brown; Lilian Reich; David Wuest; Larry Norton; William J Hoskins; David Spriggs
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1852-60.
1998: Mark Robson; Teresa A Gilewski; B Haas; D Levin; Patrick I Borgen; P Rajan; Y Hirschaut; PI Pressman; Paul Peter Rosen; M L Lesser; Larry Norton; Kenneth Offit
BRCA-associated breast cancer in young women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1642-9.
1998: Mark Robson; P Rajan; Paul Peter Rosen; Teresa A Gilewski; Y Hirschaut; PI Pressman; B Haas; Larry Norton; Kenneth Offit
BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Cancer research 1998;58(9):1839-42.
1998: Rachel B Hazan; Larry Norton
The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton.
The Journal of biological chemistry 1998;273(15):9078-84.
1998: Clifford Hudis; L Riccio; Andrew D Seidman; José Baselga; Violante E Currie; DW Fennelly; Teresa A Gilewski; David Lebwohl; Mary Ellen Moynahan; G Raptis; A Surbone; Nancy T Sklarin; Tzy-Jyun Yao; Deborah Keefe; Larry Norton
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.
Cancer investigation 1998;16(2):67-71.
1997: Clifford Hudis; L Riccio; F Holmes; Andrew D Seidman; José Baselga; Violante E Currie; DW Fennelly; Teresa A Gilewski; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; A Surbone; M Uhlenhopp; N Maickel; Tzy-Jyun Yao; S Hellmann; J Usakewicz; Gabriel N Hortobagyi; Larry Norton
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(13):2198-202.
1997: Andrew D Seidman; Clifford Hudis; John McCaffrey; William Tong; Violante E Currie; Mary Ellen Moynahan; Maria Theodoulou-Haber; I Tepler; Marc J Gollub; Larry Norton
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-72-S17-76.
1997: Larry Norton
Conceptual basis for advances in the systemic drug therapy of breast cancer.
Seminars in oncology 1997;24(4 Suppl 11):S11-2-S11-12.
1997: Larry Norton
Evolving concepts in the systemic drug therapy of breast cancer.
Seminars in oncology 1997;24(4 Suppl 10):S10-3-S10-10.
1997: Larry Norton; M J Piccart
Innovative approaches to the treatment of advanced breast cancer: introduction.
Seminars in oncology 1997;24(4 Suppl 10):S10-1-S10-2.
1997: Larry Norton
A stereotactic stand-off.
American journal of surgery 1997;173(3):151-2.
1997: José Baselga; Andrew D Seidman; Paul Peter Rosen; Larry Norton
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):43-8.
1997: Andrew D Seidman; Clifford Hudis; G Raptis; José Baselga; DW Fennelly; Larry Norton
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):20-8.
1997: Larry Norton
Truth, science, and the oncologist.
Annals of the New York Academy of Sciences 1997;809():66-71.
1997: Mark Robson; MK Dabney; G Rosenthal; S Ludwig; M H Seltzer; Teresa A Gilewski; B Haas; M Osborne; Larry Norton; F Gilbert; Kenneth Offit
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
Genetic testing 1997;1(1):47-51.
1997: DW Fennelly; Carol Aghajanian; F Shapiro; Catherine O'Flaherty; M McKenzie; C O'Connor; William Tong; Larry Norton; David Spriggs
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):187-92.
1996: Patricia N Tonin; Barbara Weber; Kenneth Offit; Fergus J. Couch; Timothy R Rebbeck; Susan L Neuhausen; A K Godwin; Mary Daly; J Wagner-Costalos; D Berman; G Grana; E Fox; Michael F Kane; R D Kolodner; michael krainer; Daniel A Haber; Jeffery Struewing; Ellen Warner; B Rosen; Caryn Lerman; Beth N Peshkin; Larry Norton; OM Serova; William D Foulkes; Judy E Garber
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.
Nature medicine 1996;2(11):1179-83.
1996: Daniel F Hayes; R C Bast; C E Desch; H Fritsche; Nancy Kemeny; J Milburn Jessup; G Y Locker; J S Macdonald; R G Mennel; Larry Norton; Peter M Ravdin; S Taube; R J Winn
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
Journal of the National Cancer Institute 1996;88(20):1456-66.
1996: Carole Oddoux; Jeffery Struewing; C M Clayton; Susan L Neuhausen; Lawrence C Brody; M Kaback; B Haas; Larry Norton; Patrick I Borgen; Suresh C Jhanwar; David E Goldgar; Harry Ostrer; Kenneth Offit
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Nature genetics 1996;14(2):188-90.
1996: Larry Norton
Management of advanced breast cancer: patient needs, challenges and new treatment options. Introduction.
Anti-cancer drugs 1996;7 Suppl 2():1-3.
1996: Clifford Hudis; Larry Norton
Adjuvant drug therapy for operable breast cancer.
Seminars in oncology 1996;23(4):475-93.
1996: Kenneth Offit; Teresa A Gilewski; P McGuire; A Schluger; H Hampel; Karen T Brown; Jeff Swensen; Susan L Neuhausen; M Skolnick; Larry Norton; David E Goldgar
Germline BRCA1 185delAG mutations in Jewish women with breast cancer.
Lancet 1996;347(9016):1643-5.
1996: Andrew D Seidman; Daniel Hochhauser; Marc J Gollub; B Edelman; Tzy-Jyun Yao; Clifford Hudis; P Francis; DW Fennelly; Teresa A Gilewski; Mary Ellen Moynahan; Violante E Currie; José Baselga; William Tong; M O'Donaghue; R Salvaggio; L Auguste; David Spriggs; Larry Norton
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1877-84.
1996: S Tross; James Herndon; A Korzun; Alice B Kornblith; David Cella; James F Holland; P Raich; A Johnson; D T Kiang; M Perloff; Larry Norton; W Wood; Jimmie C Holland
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B.
Journal of the National Cancer Institute 1996;88(10):661-7.
1996: Susan L Neuhausen; Teresa A Gilewski; Larry Norton; T Tran; P McGuire; Jeff Swensen; H Hampel; Patrick I Borgen; Karen T Brown; M Skolnick; D Shattuck-Eidens; Suresh C Jhanwar; David E Goldgar; Kenneth Offit
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
Nature genetics 1996;13(1):126-8.
1996: M Perloff; Larry Norton; A H Korzun; W C Wood; RW Carey; A Gottlieb; J C Aust; A Bank; R T Silver; F Saleh; George P Canellos; M C Perry; Raymond B Weiss; James F Holland
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1589-98.
1996: José Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; Nancy T Sklarin; Andrew D Seidman; Clifford Hudis; J Moore; Paul Peter Rosen; T Twaddell; I C Henderson; Larry Norton
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):737-44.
1996: Clifford Hudis; Andrew D Seidman; G Raptis; DW Fennelly; Teresa A Gilewski; José Baselga; Maria Theodoulou-Haber; Nancy T Sklarin; Mary Ellen Moynahan; A Surbone; Violante E Currie; David Lebwohl; M Uhlenhopp; John Crown; Larry Norton
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Seminars in oncology 1996;23(1 Suppl 1):58-64.
1996: Beryl Mc Cormick; Larry Norton; Tzy-Jyun Yao; Joachim Yahalom; Jeanne A Petrek
The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery.
The cancer journal from Scientific American 1996;2(1):39-45.
1996: Clifford Hudis; Andrew D Seidman; John Crown; Casilda Balmaceda; R Freilich; Teresa A Gilewski; T B Hakes; Violante E Currie; David Lebwohl; José Baselga; G Raptis; Marc J Gollub; M Robles; R Bruno; Larry Norton
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):58-65.
1996: S Bose; M L Lesser; Larry Norton; Paul Peter Rosen
Immunophenotype of intraductal carcinoma.
Archives of pathology & laboratory medicine 1996;120(1):81-5.
1995: J Crown; G Raptis; N Hamilton; Clifford Hudis; L Vahclat; DW Fennelly; Larry Norton
High-dose chemotherapy of breast cancer.
The Canadian journal of oncology 1995;5 Suppl 1():80-2.
1995: C E Leonard; M E Wood; B Zhen; J Rankin; D A Waitz; Larry Norton; K Howell; S Sedlacek
Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2906-15.
1995: B J Youngson; A Anelli; Kimberly Van Zee; Patrick I Borgen; Larry Norton; Paul Peter Rosen
Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma.
The American journal of surgical pathology 1995;19(12):1354-8.
1995: Larry Norton; Paul Peter Rosen; Neal Rosen
Refining the origins of breast cancer.
Nature medicine 1995;1(12):1250-1.
1995: Andrew D Seidman; Clifford Hudis; DW Fennelly; G Raptis; José Baselga; Larry Norton
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer.
Seminars in oncology 1995;22(5 Suppl 12):108-16.
1995: T A DiLorenzo; Paul B Jacobsen; Dana H Bovbjerg; H Chang; Clifford Hudis; Nancy T Sklarin; Larry Norton
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):705-11.
1995: Andrew D Seidman; Clifford Hudis; Larry Norton
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy.
Seminars in oncology 1995;22(4 Suppl 8):3-8.
1995: DW Fennelly; Larry Norton; M Sznol; T B Hakes
A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer.
Cancer 1995;75(8):2099-102.
1995: Paul Peter Rosen; M L Lesser; C D Arroyo; Milicent Cranor; Patrick I Borgen; Larry Norton
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(4):821-30.
1995: J Crown; N Hamilton; G Raptis; A Kritz; Linda Vahdat; Larry Norton
Carboplatin and etoposide in metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(4):403.
1995: Paul Peter Rosen; M L Lesser; C D Arroyo; Milicent Cranor; Patrick I Borgen; Larry Norton
Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.
Cancer 1995;75(6):1320-6.
1995: Paul B Jacobsen; Dana H Bovbjerg; M D Schwartz; Clifford Hudis; Teresa A Gilewski; Larry Norton
Conditioned emotional distress in women receiving chemotherapy for breast cancer.
Journal of consulting and clinical psychology 1995;63(1):108-14.
1995: J Crown; Larry Norton
Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 4():21-6.
1995: C Leonard; M Corkill; J Tompkin; B Zhen; D Waitz; Larry Norton; J Kinzie
Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):47-53.
1995: John Crown; G Raptis; N Hamilton; DW Fennelly; Linda Vahdat; Larry Norton
High-dose chemotherapy of breast cancer: current status and developmental strategies.
European journal of cancer (Oxford, England : 1990) 1995;31A(5):809-11.
1994: J G Schneider; John Crown; C Wasserheit; A Kritz; G Wong; Lilian Reich; Larry Norton; Malcolm A S Moore
Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
Bone marrow transplantation 1994;14(6):877-84.
1994: DW Fennelly; C Wasserheit; J Schneider; T Hakes; Lilian Reich; J Curtin; Tzy-Jyun Yao; M Markman; Larry Norton; John Crown
Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Cancer research 1994;54(23):6137-42.
1994: F Shapiro; Tzy-Jyun Yao; G Raptis; Lilian Reich; Larry Norton; Malcolm A S Moore
Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer.
Blood 1994;84(10):3567-74.
1994: Andrew D Seidman; Larry Norton; B S Reichman; John Crown; Tzy-Jyun Yao; T B Hakes; David Lebwohl; Teresa A Gilewski; Clifford Hudis; A Surbone
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.
Oncology 1994;51 Suppl 1():33-9.
1994: Larry Norton
Salvage chemotherapy of breast cancer.
Seminars in oncology 1994;21(4 Suppl 7):19-24.
1994: Russell Portenoy; Howard T Thaler; Alice B Kornblith; J M Lepore; H Friedlander-Klar; Nessa Coyle; T Smart-Curley; Nancy Kemeny; Larry Norton; W Hoskins
Symptom prevalence, characteristics and distress in a cancer population.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1994;3(3):183-9.
1994: W C Wood; D R Budman; A H Korzun; M R Cooper; J Younger; R D Hart; A Moore; J A Ellerton; Larry Norton; C R Ferree
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.
The New England journal of medicine 1994;330(18):1253-9.
1994: O A Armas; W L Gerald; M L Lesser; C D Arroyo; Larry Norton; Paul Peter Rosen
Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma.
The American journal of surgical pathology 1994;18(2):158-66.
1994: A Surbone; Larry Norton
[Kinetics of breast neoplasms].
Minerva medica 1994;85(1-2):7-16.
1994: J F Holland; S Bhardwaj; Larry Norton
Re: "We may be lost, but we're sure makin' good time".
Cancer investigation 1994;12(2):270-2.
1994: Russell Portenoy; Howard T Thaler; Alice B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; Nessa Coyle; Nancy Kemeny; Larry Norton
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.
European journal of cancer (Oxford, England : 1990) 1994;30A(9):1326-36.
1994: R Foa; Larry Norton; Andrew D Seidman
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
International journal of clinical & laboratory research 1994;24(1):6-14.
1993: C Leonard; C L Harlow; C Coffin; J Drose; Larry Norton; J Kinzie
Use of ultrasound to guide radiation boost planning following lumpectomy for carcinoma of the breast.
International journal of radiation oncology, biology, physics 1993;27(5):1193-7.
1993: A Surbone; Larry Norton
Kinetic concepts in the treatment of breast cancer.
Annals of the New York Academy of Sciences 1993;698():48-62.
1993: Clifford Hudis; Larry Norton
Systemic adjuvant therapy for breast cancer.
Current opinion in oncology 1993;5(6):982-90.
1993: Paul B Jacobsen; Dana H Bovbjerg; M D Schwartz; Michael A Andrykowski; A D Futterman; Teresa A Gilewski; Larry Norton; William H Redd
Formation of food aversions in cancer patients receiving repeated infusions of chemotherapy.
Behaviour research and therapy 1993;31(8):739-48.
1993: Paul Peter Rosen; S Groshen; D W Kinne; Larry Norton
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2090-100.
1993: J Baselga; Larry Norton; H Masui; A Pandiella; K Coplan; W H Miller; J Mendelsohn
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Journal of the National Cancer Institute 1993;85(16):1327-33.
1993: Stuart M Lichtman; M J Ratain; David A Van Echo; Gary Rosner; Merrill J Egorin; Daniel R Budman; N J Vogelzang; Larry Norton; R L Schilsky
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Journal of the National Cancer Institute 1993;85(16):1319-26.
1993: Andrew D Seidman; Larry Norton; B S Reichman; John Crown; Tzy-Jyun Yao; Robert T Heelan; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.
Seminars in oncology 1993;20(4 Suppl 3):40-5.
1993: Ellen Yorke; Z Fuks; Larry Norton; W Whitmore; C Clifton Ling
Modeling the development of metastases from primary and locally recurrent tumors: comparison with a clinical data base for prostatic cancer.
Cancer research 1993;53(13):2987-93.
1993: Larry Norton
Kinetic concepts in the treatment of breast cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;127():1-6.
1993: S Bhardwaj; James F Holland; Larry Norton
An intensive sequenced adjuvant chemotherapy regimen for breast cancer.
Cancer investigation 1993;11(1):6-9.
1993: Beryl Mc Cormick; Colin B Begg; Larry Norton; T J Yao; D Kinne
Timing of radiotherapy in the treatment of early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):191-3.
1992: Dana H Bovbjerg; William H Redd; Paul B Jacobsen; Sharon Manne; Kathryn L Taylor; A Surbone; John Crown; Larry Norton; Teresa A Gilewski; Clifford Hudis
An experimental analysis of classically conditioned nausea during cancer chemotherapy.
Psychosomatic medicine 1992;54(6):623-37.
1992: Howard I Scher; Larry Norton
Chemotherapy for urothelial tract malignancies: breaking the deadlock.
Seminars in surgical oncology 1992;8(5):316-41.
1992: Larry Norton
Evolving concepts in the adjuvant systemic therapy of operable breast cancer.
Cancer treatment and research 1992;60():3-25.
1991: Larry Norton
Metastatic breast cancer. Length and quality of life.
The New England journal of medicine 1991;325(19):1370-1.
1991: J Crown; Larry Norton
Adjuvant systemic therapy for early breast cancer.
Seminars in surgical oncology 1991;7(5):283-90.
1991: Daniel F Hayes; R Mesa-Tejada; L D Papsidero; G A Croghan; A H Korzun; Larry Norton; W Wood; J A Strauchen; M Grimes; Raymond B Weiss
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1113-23.
1991: Larry Norton; R Day
Potential innovations in scheduling of cancer chemotherapy.
Important advances in oncology 1991;():57-72.
1991: J Crown; R Lipzstein; S Cohen; M Goldsmith; N Wisch; P A Paciucci; L Silverman; M Weiner; I Jaffrey; Larry Norton
Chemotherapy of metastatic Merkel cell cancer.
Cancer investigation 1991;9(2):129-32.
1991: Nancy A Dawson; M E Costanza; A H Korzun; G H Clamon; M Pollak; N J Vogelzang; RW Carey; Larry Norton
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Medical and pediatric oncology 1991;19(4):283-8.
1990: A J Gottlieb; James Robert Anderson; S J Ginsberg; Clara D Bloomfield; Larry Norton; M Barcos; B A Peterson; N Nissen; E S Henderson; J F Holland
A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
Cancer 1990;66(9):1888-96.
1990: Q S Ringenberg; Kathleen J Propert; Hyman Muss; Raymond B Weiss; R L Schilsky; C Modeas; M C Perry; Larry Norton; M Green
Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
Investigational new drugs 1990;8(2):221-6.
1990: Larry Norton
Biology of residual breast cancer after therapy: a kinetic interpretation.
Progress in clinical and biological research 1990;354A():109-32.
1989: J G Wall; Raymond B Weiss; Larry Norton; M Perloff; M A Rice; A H Korzun; W C Wood
Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study.
The American journal of medicine 1989;87(5):501-4.
1988: Larry Norton
A Gompertzian model of human breast cancer growth.
Cancer research 1988;48(24 Pt 1):7067-71.
1988: Larry Norton
Implications of growth kinetic concepts for cancer chemoprevention.
Cancer investigation 1988;6(5):625-8.
1987: R B Jones; J F Holland; S Bhardwaj; Larry Norton; C Wilfinger; A Strashun
A phase I-II study of intensive-dose adriamycin for advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(2):172-7.
1987: S J Ginsberg; J R Anderson; A J Gottlieb; Clara D Bloomfield; Larry Norton; M Barcos; J F Holland
A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851.
NCI monographs : a publication of the National Cancer Institute 1987;(5):77-80.
1986: M E Ellis; Raymond B Weiss; A H Korzun; M A Rice; Larry Norton; M Perloff; G J Lesnick; W C Wood
Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer. A cancer and leukemia group B (CALGB) study.
American journal of clinical oncology 1986;9(6):533-6.
1986: Larry Norton; R Simon
The Norton-Simon hypothesis revisited.
Cancer treatment reports 1986;70(1):163-9.
1985: Larry Norton
Implications of kinetic heterogeneity in clinical oncology.
Seminars in oncology 1985;12(3):231-49.
1984: A P Chahinian; Larry Norton; James F Holland; L Szrajer; R D Hart
Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma.
Cancer research 1984;44(4):1688-92.